ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MRNS Marinus Pharmaceuticals Inc

1.42
-0.04 (-2.74%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 866,191
Bid Price 1.42
Ask Price 1.48
News -
Day High 1.585

Low
1.11

52 Week Range

High
11.26

Day Low 1.41
Share Name Share Symbol Market Stock Type
Marinus Pharmaceuticals Inc MRNS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.04 -2.74% 1.42 17:09:10
Open Price Low Price High Price Close Price Previous Close
1.47 1.41 1.585 1.42 1.46
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
3,849 866,191 US$ 1.46 US$ 1,262,224 - 1.11 - 11.26
Last Trade Type Quantity Price Currency
18:32:17 20 US$ 1.48 USD

Marinus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
77.59M 54.64M - 30.99M -141.41M -2.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Marinus Pharmaceuticals News

Date Time Source News Article
5/24/202405:35Edgar (US Regulatory)Form 8-K - Current report
5/17/202406:05Edgar (US Regulatory)Form 8-K - Current report
5/17/202406:00Business WireMarinus Pharmaceuticals Announces Key Business Updates for..
5/08/202406:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/08/202406:05Edgar (US Regulatory)Form 8-K - Current report
5/08/202406:00Business WireMarinus Pharmaceuticals Provides Business Update and Reports..
5/02/202407:00Business WireMarinus Pharmaceuticals to Present at the RBC Capital..
5/01/202407:00Business WireMarinus Pharmaceuticals to Provide Business Update and..
4/15/202406:00Business WireMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE..
4/05/202415:00Business WireMarinus Pharmaceuticals Announces Inducement Grants Under..
3/27/202407:41Business WireMarinus Pharmaceuticals Comments on Patent Challenge by Ovid..
3/05/202415:14Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MRNS Message Board. Create One! See More Posts on MRNS Message Board See More Message Board Posts

Historical MRNS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.311.5851.2851.481,429,1410.118.40%
1 Month1.501.771.271.401,399,335-0.08-5.33%
3 Months8.839.691.112.142,203,954-7.41-83.92%
6 Months6.8511.261.113.511,250,191-5.43-79.27%
1 Year7.2111.261.115.22968,491-5.79-80.31%
3 Years16.9119.831.116.39553,528-15.49-91.60%
5 Years4.2720.040.774.441,038,122-2.85-66.74%

Marinus Pharmaceuticals Description

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Your Recent History

Delayed Upgrade Clock